Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

James K. McCloskey II, MD
Published: Thursday, Dec 21, 2017



James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).

CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.

The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.
 


James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).

CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.

The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x